Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Photofirst
- Development stage
- Preclinical
- Lead developer
- Eris Oaknet Healthcare
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Photofirst** is a topical cream marketed by Oaknet Healthcare for daylight-assisted, home-based management of vitiligo and psoriasis. The formulation contains alpha-glucosyl hesperidin and ethylhexyl benzoate and is applied to affected skin before limited direct daylight exposure. Product listings describe it as a device-free alternative intended to support narrowband UVB-like phototherapy; however, independently verifiable clinical-program, regulatory, patent, or peer-reviewed evidence for the specific product was not identified. ([apollopharmacy.in](https://www.apollopharmacy.in/otc/photofirst-cream-50-gm))
- Brand names
- Photofirst
- Other names
- Photofirst Cream
Beyond the preview
Go deeper on Photofirst.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Photofirst.